(Q54127154)

25 May 2018

review article

1 reference

title

The utility of aminoglycosides in an era of emerging drug resistance. (English)

1 reference

25 May 2018

2

Noskin GA

1 reference

25 May 2018

Lance R Peterson

5

object named as

Peterson LR

1 reference

25 May 2018

author name string

Zembower TR

1

1 reference

25 May 2018

Postelnick MJ

3

1 reference

25 May 2018

Nguyen C

4

1 reference

25 May 2018

publication date

1 May 1998

1 reference

25 May 2018

International Journal of Antimicrobial Agents

published in

1 reference

25 May 2018

volume

10

1 reference

25 May 2018

issue

2

1 reference

25 May 2018

page(s)

95-105

1 reference

25 May 2018

Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycoside therapy. Current use and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycoside research 1975-1985: prospects for development of improved agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Strategies in aminoglycoside use and impact upon resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

1 reference

7 January 2021

Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

The lethal action of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycoside antibiotics in infectious diseases. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycosides: do we need new agents?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Prudent use of the aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Future perspectives of aminoglycoside therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycosides in the treatment of bacteraemic infections in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Combination therapy and monotherapy in the treatment of severe infection in the immunocompromised host

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

In vitro models for the study of combination antibiotic therapy in neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Combination therapy: a way to limit emergence of resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Effect of highly potent antipseudomonal beta-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Management of intra-abdominal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Use of aminoglycosides in surgical infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycosides in gynecologic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

In-vitro killing activity of combinations of beta-lactam agents with aminoglycosides against penicillin-resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Mechanisms of gentamicin resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Surveillance of aminoglycoside resistance. European data

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Prevalence and mechanisms of aminoglycoside resistance. A ten-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycoside resistance: a worldwide perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Mechanisms of resistance to aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Review of epidemic aminoglycoside resistance worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Single daily dose of aminoglycosides--a concept whose time has not yet come

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycosides--50 years on

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Once-daily dosing of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Once-daily aminoglycoside therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

What is the cost of nephrotoxicity associated with aminoglycosides?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycoside nephrotoxicity and its predictability

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Determinants of efficacy and toxicity of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

Aminoglycoside nephrotoxicity: a double blind prospective randomized study of gentamicin and tobramycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900033-8

7 January 2021

10.1016/S0924-8579(98)00033-8

Identifiers

DOI

1 reference

25 May 2018

1 reference

25 May 2018